Answers are grounded in this paper and cite their sources.
This systematic review suggests that reduced doses of Enzalutamide in CRPC may maintain therapeutic efficacy in selected patients while improving tolerability. However, inconsistent findings and methodological limitations highlight the need for prospective randomized trials to define optimal and individualized dosing strategies.
No takes yet. Share an insight, caveat, or question.
Belabaci et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: